Alexion Pharmaceuticals Inc. has begun recruitment in a multinational study of ALXN1210, its longer- longer-acting antibody follow-up to its complement C5 inhibitor Soliris (eculizumab), in patients with paroxysmal nocturnal hemoglobinuria (PNH), which it hopes will show the product can be effective given every eight weeks, a significantly reduced dosing burden compared with the older product’s fortnightly schedule.
With Soliris, which was first launched in 2007, Alexion has successfully carved out a multi-blockbuster position through high prices, and...






